Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adaptimmune Ther ADR
(NQ:
ADAP
)
1.270
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
985,969
Open
1.260
Bid (Size)
1.220 (4)
Ask (Size)
1.270 (14)
Prev. Close
1.270
Today's Range
1.210 - 1.280
52wk Range
0.4200 - 2.050
Shares Outstanding
1,534,472,670
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Adaptimmune to Participate in Two Bank Conferences this September
August 28, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to...
Via
Newsfile
ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 12, 2024
ADAP stock results show that Adaptimmune Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
+70.24%
+70.24%
1 Month
N/A
N/A
3 Month
+18.69%
+18.69%
6 Month
-14.19%
-14.19%
1 Year
+60.76%
+60.76%
More News
Read More
Adaptimmune Reports Q2 2024 Financial and Business Updates
August 12, 2024
Via
Newsfile
Exposures
Product Safety
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
August 12, 2024
Via
Benzinga
The Latest Analyst Ratings For Adaptimmune Therapeutics
August 05, 2024
Via
Benzinga
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
May 31, 2024
Via
Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
August 02, 2024
Via
Benzinga
Exposures
Product Safety
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
August 01, 2024
From
Adaptimmune Therapeutics plc
Via
Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
July 03, 2024
Via
InvestorPlace
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
June 03, 2024
Via
Newsfile
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
May 31, 2024
Via
AB Newswire
Exposures
Product Safety
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 31, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 31, 2024
Via
Benzinga
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
May 31, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 31, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
May 30, 2024
Via
Benzinga
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
May 30, 2024
Via
Newsfile
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 15, 2024
Via
InvestorPlace
Adaptimmune Reports Q1 2024 Financial and Business Updates
May 15, 2024
Via
Newsfile
Exposures
Product Safety
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
May 15, 2024
Via
Newsfile
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
May 01, 2024
Via
Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
April 19, 2024
Via
Benzinga
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
April 12, 2024
Via
Newsfile
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
March 27, 2024
Via
Newsfile
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 08, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.